An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene

Trial Profile

An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Dianhydrogalactitol (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Del Mar Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2018 According to a DelMar Pharmaceuticals media release, dose-confirmation (n=4) studying 20 and 30 mg/m2/day cycles has been completed.
    • 17 Apr 2018 According to a DelMar Pharmaceuticals media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting (2018).
    • 21 Nov 2017 According to a DelMar Pharmaceuticals media release, an overview of the trial design has been presented at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top